WuXi Biologics to Invest $389 Million in New Biomanufacturing Facility
The company will invest EUR 325 million (US$389 million) in a new biomanufacturing facility in Ireland using single-use bioreactors.
On April 30, 2018, WuXi Biologics, part of WuXi AppTech, announced plans to invest EUR 325 million (US$389 million) in a new biomanufacturing facility in Mullagharlin, Dundalk, County Louth, Ireland.
According to the company, the new facility will use multiple single-use bioreactors for commercial biomanufacturing and is designed to be able to run continuous bioprocessing. A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will also be installed.
The site will be on a 26-hectare campus and is the company’s first site outside of China. The investment is expected to create over 400 skilled jobs over a five-year span, as well as add approximately 700 construction jobs.
The project is supported by the Irish Government through IDA Ireland, an economic development body for Ireland.
Source: WuXi Biologics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
